Previous 10 | Next 10 |
Stock Traders Daily has produced this trading report using a proprietary method. This methodology seeks to optimize the entry and exit levels to maximize results and limit risk, and it is also applied to Index options, ETFs, and futures for our subscribers. This report optimizes tradi...
BDSI is down after lower guidance over the Alvogen unauthorised launch. However, the key issue is the patent litigation, still ongoing since 2018. If this issue is resolved in favour of BDSI, current lows could be an opportunity. For further details see: BioDelivery Scie...
4 Reddit Penny Stocks to Watch in Mid-November 2021 If you look for penny stocks on Reddit, you are not alone. Many investors have turned to the social media site as a way to find potentially valuable penny stocks to buy . And while it may seem as easy as stumbling across frequently...
The following slide deck was published by BioDelivery Sciences International, Inc. in conjunction with their 2021 Q3 earnings call. For further details see: BioDelivery Sciences International, Inc. 2021 Q3 - Results - Earnings Call Presentation
Stock Traders Daily has produced this trading report using a proprietary method. This methodology seeks to optimize the entry and exit levels to maximize results and limit risk, and it is also applied to Index options, ETFs, and futures for our subscribers. This report optimizes tradi...
Image source: The Motley Fool. BioDelivery Sciences International, inc (NASDAQ: BDSI) Q3 2021 Earnings Call Nov 3, 2021 , 8:30 a.m. ET Operator Continue reading For further details see: BioDelivery Sciences International, inc (BDSI) Q3 20...
BioDelivery Sciences International, Inc. (BDSI) Q3 2021 Earnings Conference Call November 3, 2021 8:30 AM ET Company Participants Terry Coelho – Executive Vice President and Chief Financial Officer Jeff Bailey – Chief Executive Officer Scott Plesha – President and Chief C...
BioDelivery Sciences (NASDAQ:BDSI): Q3 GAAP EPS of $0.07 beats by $0.01. Revenue of $41.09M (+4.2% Y/Y) misses by $0.95M. Shares +2.44% PM. Press Release Closed acquisition of ELYXYB, the first FDA-approved, ready-to-use oral solution for acute migraine with potential long-term peak sales opp...
Total Net Revenue of $41.1 Million, an Increase of 4% versus Prior Year Strong profitability with GAAP EPS of $0.07, EBITDA Margin of 27% and $7.0 million Operating Cash Flow Closed acquisition of ELYXYB, the first FDA-approved, ready-to-use oral solution for acute migrain...
BioDelivery Sciences (NASDAQ:BDSI) is scheduled to announce Q3 earnings results on Wednesday, November 3rd, before market open. The consensus EPS Estimate is $0.08 and the consensus Revenue Estimate is $42.04M (+6.7% Y/Y). BioDelivery Sciences provided a Q3 revenue forecast in the range of $3...
News, Short Squeeze, Breakout and More Instantly...
BioDelivery Sciences International Inc. Company Name:
BDSI Stock Symbol:
NASDAQ Market:
BioDelivery Sciences International Inc. Website:
35 years industry experience including as CEO and founder of public company Stephen Squinto steps down as Chair for new role MILAN, Italy and NEW YORK, April 27, 2022 (GLOBE NEWSWIRE) -- Genenta Science (NASDAQ: GNTA), a clinical-stage biotechnology company pioneering the developm...
Stock Traders Daily has produced this trading report using a proprietary method. This methodology seeks to optimize the entry and exit levels to maximize results and limit risk, and it is also applied to Index options, ETFs, and futures for our subscribers. This report optimizes tradi...
Stock Traders Daily has produced this trading report using a proprietary method. This methodology seeks to optimize the entry and exit levels to maximize results and limit risk, and it is also applied to Index options, ETFs, and futures for our subscribers. This report optimizes tradi...